Table 3. Analysis of normalized cycle frequency during drug application.

Group A				Group B
Condition	n	Mean	S.E.M	Condition	n	Mean	S.E.M	P
HH St. 26 Baseline	75	1.000	0.037	HH St. 26 10 μM DTC	50	0.000	0.000	<0.0001
HH St. 26 Baseline	98	1.000	0.021	HH St.26 10 μM Scopolamine	94	0.481	0.039	<0.0001
HH St. 26 Baseline	29	1.000	0.056	HH St. 26 10 μM PTX	28	0.259	0.064	<0.0001
HH St. 30 Baseline	43	1.000	0.081	HH St. 30 10 μM DTC	45	0.000	0.000	<0.0001
HH St. 30 Baseline	90	1.000	0.013	HH St. 30 2 μM Scopolamine	88	1.858	0.039	<0.0001
HH St. 30 Baseline	86	1.000	0.006	HH St. 30 10 μM Scopolamine	81	0.6733	0.024	<0.0001
HH St. 30 Baseline	69	1.000	0.010	HH St. 30 10 μM PTX	65	0.5477	0.016	<0.0001

n = number of neurons examined; ≥3 embryos examined per condition.